Cargando…

Living kidney transplantation without perioperative anticoagulation therapy for a patient with heparin‐induced thrombocytopenia

INTRODUCTION: Heparin‐induced thrombocytopenia is an antibody‐mediated acquired prothrombotic state induced by heparin exposure. The risk of thromboembolic diseases in kidney transplantation with heparin‐induced thrombocytopenia without perioperative anticoagulation has not been determined. CASE PRE...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishida, Hayato, Fukuhara, Hiroki, Yamagishi, Atsushi, Hosoya, Noriyuki, Ichiyanagi, Osamu, Sakurai, Toshihiko, Naito, Sei, Yamanobe, Takuya, Kato, Tomoyuki, Tsuchiya, Norihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292195/
https://www.ncbi.nlm.nih.gov/pubmed/32743478
http://dx.doi.org/10.1002/iju5.12148
Descripción
Sumario:INTRODUCTION: Heparin‐induced thrombocytopenia is an antibody‐mediated acquired prothrombotic state induced by heparin exposure. The risk of thromboembolic diseases in kidney transplantation with heparin‐induced thrombocytopenia without perioperative anticoagulation has not been determined. CASE PRESENTATION: A 64‐year‐old male hemodialysis patient with heparin‐induced thrombocytopenia was referred to our hospital for living kidney transplantation. Anti‐heparin‐induced thrombocytopenia antibody was positive at the time of referral; however, it turned negative 4 months after heparin cessation during hemodialysis sessions. Living kidney transplantation by donation from his wife was performed using the standard technical procedure. Both heparinization and application of medical equipment containing heparin were avoided; however, no anticoagulant was administered intra‐ and postoperatively. The graft kidney functioned immediately, and no thromboembolic event related to heparin‐induced thrombocytopenia occurred. CONCLUSION: Kidney transplantation without perioperative anticoagulation therapy after disappearance of anti‐heparin‐induced thrombocytopenia antibody is a well‐tolerated treatment option for patients with end‐stage kidney disease.